Related references
Note: Only part of the references are listed.What is active acromegaly and which parameters do we have?
S. J. C. M. M. Neggers et al.
CLINICAL ENDOCRINOLOGY (2012)
Gender Difference in the Neuroendocrine Regulation of Growth Hormone Axis by Selective Estrogen Receptor Modulators
Vita Birzniece et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience
Francesco M. Minuto et al.
PITUITARY (2012)
Comparison of two immunoassays in the determination of IGF-I levels and its correlation with oral glucose tolerance test (OGTT) and with clinical symptoms in acromegalic patients
Laura Boero et al.
PITUITARY (2012)
Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naive to medical therapy and radiation: what to follow, GH or IGF-1 values?
Jessica A. Brzana et al.
PITUITARY (2012)
Medical Therapy of Acromegaly
U. Ploeckinger
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2012)
Clinical laboratory indices in the treatment of acromegaly
David R. Clemmons
CLINICA CHIMICA ACTA (2011)
Consensus Statement on the Standardization and Evaluation of Growth Hormone and Insulin-like Growth Factor Assays
David R. Clemmons
CLINICAL CHEMISTRY (2011)
Growth hormone nadir during oral glucose load depends on waist circumference, gender and age: normative data in 231 healthy subjects
Annamaria Colao et al.
CLINICAL ENDOCRINOLOGY (2011)
Hypothesis: Extra-hepatic acromegaly: a new paradigm?
Sebastian J. Neggers et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Clinical and metabolic characteristics of acromegalic patients with high IGF1/normal GH levels during somatostatin analog treatment
Maria Matta et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Limited utility of oral glucose tolerance test in biochemically active acromegaly
Antonio Ribeiro-Oliveira et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Endoscopic Transsphenoidal Surgery for Acromegaly: Remission Using Modern Criteria, Complications, and Predictors of Outcome
John A. Jane et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Excess mortality for patients with residual disease following resection of pituitary adenomas
Michael E. Sughrue et al.
PITUITARY (2011)
Clinical, quality of life, and economic value of acromegaly disease control
A. Ben-Shlomo et al.
PITUITARY (2011)
The role of insulin-like growth factor-1 and growth hormone in the mortality of patients with acromegaly after trans-sphenoidal surgery
Tzu-En Wu et al.
GROWTH HORMONE & IGF RESEARCH (2010)
Measurement of human growth hormone by immunoassays: Current status, unsolved problems and clinical consequences
Martin Bidlingmaier et al.
GROWTH HORMONE & IGF RESEARCH (2010)
Discordant Nadir GH After Oral Glucose and IGF-I Levels on Treated Acromegaly: Refining the Biochemical Markers of Mild Disease Activity
P. C. L. Elias et al.
HORMONE AND METABOLIC RESEARCH (2010)
A Consensus on Criteria for Cure of Acromegaly
A. Giustina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Acromegaly: a review of current medical therapy and new drugs on the horizon
Maria Fleseriu et al.
NEUROSURGICAL FOCUS (2010)
Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide AutogelA® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension
Shlomo Melmed et al.
PITUITARY (2010)
The value of the oral glucose tolerance test, random serum growth hormone and mean growth hormone levels in assessing the postoperative outcome of patients with acromegaly
N. Karavitaki et al.
CLINICAL ENDOCRINOLOGY (2009)
Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly
M. Sherlock et al.
CLINICAL ENDOCRINOLOGY (2009)
Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant?
Pamela U. Freda
CLINICAL ENDOCRINOLOGY (2009)
D3 GH receptor polymorphism is not associated with IGF1 levels in untreated acromegaly
Peter Kamenicky et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Influence of Growth Hormone Receptor d3 and Full-Length Isoforms on Biochemical Treatment Outcomes in Acromegaly
Antonio Bianchi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
The Utility of Oral Glucose Tolerance Testing for Diagnosis and Assessment of Treatment Outcomes in 166 Patients with Acromegaly
John D. Carmichael et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly
I. M. Holdaway et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
The influence of age on the GH-IGF1 axis in patients with acromegaly
Keiji Tanimoto et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR®
Evelyn Oliveira Machado et al.
GROWTH HORMONE & IGF RESEARCH (2008)
Divergence between growth hormone and insulin-like growth factor-I concentrations in the follow-up of acromegaly
Orsalia Alexopoulou et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant
S. J. C. M. M. Neggers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly
Moises Mercado et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Growth hormone response during oral glucose tolerance test:: The impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index
Ayman M. Arafat et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Mortality in acromegaly: A meta analysis
O. M. Dekkers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Acromegaly associated with type 2 diabetes showing normal IGF-1 levels under poorly controlled glycemia
Dong Jun Lim et al.
ENDOCRINE JOURNAL (2007)
Serum IGF-I levels in the diagnosis and monitoring of acromegaly
A. M. Brooke et al.
PITUITARY (2007)
Adequacy of current postglucose GH nadir limit (< 1 μg/1) to define long-lasting remission of acromegalic disease
Cristina L. Ronchi et al.
CLINICAL ENDOCRINOLOGY (2007)
Value of insulin-like growth factor system markers in the assessment of growth hormone status
David R. Clemmons
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2007)
Medical progress: Acromegaly
Shlomo Melmed
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly
Shih-Che Hua et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Serum insulin-like growth factor-I measurement in the follow-up of treated acromegaly: Comparison of four immunoassays
C. Massart et al.
CLINICA CHIMICA ACTA (2006)
Effect of sex and assay method on serum concentrations of growth hormone in patients with acromegaly and in healthy controls
H Markkanen et al.
CLINICAL CHEMISTRY (2006)
Biochemical evaluation of disease activity after pituitary surgery in acromegaly:: a critical analysis of patients who spontaneously change disease status
AL Espinosa-de-los-Monteros et al.
CLINICAL ENDOCRINOLOGY (2006)
Postoperative evaluation of patients with acromegaly: Clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels
RA Feelders et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Quality of life (QOL) in patients with acromegaly is severely impaired: Use of a novel measure of QOL: Acromegaly Quality of Life Questionnaire
SV Rowles et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Morbidity after long-term remission for acromegaly: Persisting joint-related complaints cause reduced quality of life
NR Biermasz et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly
JJ Puder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria
CL Ronchi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
The 'bio-assay' quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations
IE Bonapart et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly
J Ayuk et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Remission criteria for the follow-up of patients with acromegaly
S Gullu et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Factors influencing mortality in acromegaly
IM Holdaway et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Significance of abnormal nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels
PU Freda et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system
F Minuto et al.
CLINICAL ENDOCRINOLOGY (2004)
Determinants of survival in treated acromegaly in a single center: Predictive value of serial insulin-like growth factor I measurements
NR Biermasz et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Estrogen regulation of growth hormone action
KC Leung et al.
ENDOCRINE REVIEWS (2004)
Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease
M Mercado et al.
HORMONE RESEARCH (2004)
Variability and reliability of single serum IGF-I measurements: Impact on determining predictability of risk ratios in disease development
D Milani et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Long-term treatment outcome in acromegaly
IM Holdaway et al.
GROWTH HORMONE & IGF RESEARCH (2003)
Current concepts in the biochemical assessment of the patient with acromegaly
PU Freda
GROWTH HORMONE & IGF RESEARCH (2003)
Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: Predictive value of short-term results?
R Cozzi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Molecular heterogeneity of human GH: From basic research to clinical implications
CL Boguszewski
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2003)
Use of the oral glucose tolerance test to define remission in acromegaly
H Vierhapper et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2003)
Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature
G Minniti et al.
ENDOCRINE-RELATED CANCER (2003)
Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly
AL Espinosa-De-Los-Monteros et al.
JOURNAL OF NEUROSURGERY (2002)
Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly
C Parkinson et al.
CLINICAL ENDOCRINOLOGY (2002)
Gender- and age-related differences in the endocrine parameters of acromegaly
A Colao et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2002)
Insulin-like growth factor 1 measurement in diagnosis and management of acromegaly
SR Peacey et al.
ANNALS OF CLINICAL BIOCHEMISTRY (2001)
Metabolic functions of liver-derived (endocrine) insulin-like growth factor I
OGP Isaksson et al.
HORMONE RESEARCH (2001)
Share Paper
